Researchers from the University of Oxford’s Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine.
Influenza is thought to be a highly variable virus, able to mutate and escape immunity built up in the population due to its circulation in previous seasons. However, influenza seasons tend to be dominated by a limited number of antigenically and genetically distinct influenza viruses. This creates a paradox as influenza is thought of as being highly variable while in reality influenza seasons are dominated by only a few strains.
Mathematical models produced in Professor Sunetra Gupta’s group at the University of Oxford over the past 20 years have sought to find an answer to this paradox. Finally, through a collaborative approach across multiple departments, the group believes they have the answer, demonstrated in a paper published today in Nature Communications.
Dr Craig Thompson said: ‘The integrated approach to vaccine design that we have applied to flu has to the potential to be applied to other previously intractable pathogens and could revolutionise the way we develop vaccines.’
Professor Sunetra Gupta said: ‘I think this work serves a good example of how evolutionary models can have translational impact. We have gone from a prediction of a mathematical model to a blueprint for a universal influenza vaccine. The outstanding teamwork coordinated by Dr Thompson is what made it all possible.’
The research team theorized that parts of the virus targeted by the immune system are, in fact, limited in variability and act as constraints on the evolution of the virus. Dr Craig Thompson in Professor Gupta’s group has now identified the location of these regions of limited variability. He has shown that such locations are targeted naturally by the immune system and through vaccination studies has shown that regions of influenza viruses that circulated in 2006 and 1977 were able to protect against infection with an influenza virus that last circulated in 1934.
The results of these studies can be exploited to create a novel type of ‘universal’ or broadly protective influenza vaccine, which once administered would provide lifelong protection against influenza. The team also hopes to apply the approach to other viruses such as HIV and HCV and believes that they can use it to produce a vaccine that protects against the common cold. The novel approach to vaccine design is outlined in the paper published in Nature Communications. Furthermore, such vaccines should be able to be produced in a low-cost manner, enabling healthcare providers such as the NHS to save money, unlike many new vaccines and drugs coming to the market.
This study also presents one of the first examples of where a mathematical model of the evolutionary dynamics of an infectious disease has led to the experimental identification of a novel vaccine target. The novel approach won an MRC Confidence in Concept Award in 2016, a Royal Society Translational Award in 2017 and an ERC Proof of Concept grant in 2018.
The WHO estimates that influenza kills 260,000-650,000 people and causes 3-5 million cases of severe illness each year. This burden typically falls on the elderly and young children, especially in developing countries. The best way to protect against influenza is through vaccination, although the problem with this is that the current influenza vaccine has to be administered each year and varies in its effectiveness.
The Latest on: Universal flu vaccine
via Google News
The Latest on: Universal flu vaccine
- Kenya: Battle Against Flu Gets a Boost With Sh1.2 Billion Granton September 5, 2019 at 12:10 am
The world could get a universal vaccine that is effective against all strains of influenza viruses. This is after eight scientists received funding from the Bill & Melinda Gates Foundation to ...
- Battle against flu gets a boost with Sh1.2bn granton September 3, 2019 at 11:03 pm
The world could get a universal vaccine that is effective against all strains of influenza viruses. This is after eight scientists received funding from the Bill & Melinda Gates Foundation to develop ...
- Oregon hospital researching the development of a universal flu vaccineon August 30, 2019 at 2:34 pm
PORTLAND, Ore. (KWCH) - Oregon Health & Science University Hospital is researching the creation of a universal flu vaccine with the help of a grant from the Bill and Melinda Gates Foundation. The ...
- Oregon researchers aiming to make your yearly flu shot a thing of the paston August 30, 2019 at 1:48 am
Last year marked 100 years since the deadliest flu pandemic in history, known as the 1918 influenza pandemic. The centennial spurred the Bill and Melinda Gates Foundation to start the Grand Challenge ...
- Seasonal Influenza Vaccines Market Growth Rate, Manufacturers, Market Dynamics, Market Overviewon August 29, 2019 at 4:40 pm
Also, National Institute of Allergy and Infectious Disease (NIAID) is engaged in developing new strategic plan to develop novel, safe and effective universal influenza vaccine. Various government ...
- OHSU receives grant from Gates Foundation to develop universal flu vaccineon August 29, 2019 at 2:46 pm
Oregon Health & Science University received a grant from the Gates Foundation to develop the Holy Grail of vaccines: a universal flu vaccine. OHSU is one of about six institutions that are splitting ...
- Gates Foundation donates $12M to universal flu vaccine researchon August 29, 2019 at 8:59 am
Up to eight research teams will receive about $12 million in funding to research a universal flu vaccine, thanks to grants from the Bill and Melinda Gates Foundation and the philanthropic organization ...
- With new grants, Gates Foundation takes an early step toward a universal flu vaccineon August 29, 2019 at 1:46 am
Scientific teams from inside and outside the world of influenza research have been awarded funding to try to unlock mysteries that could provide the foundation for a future universal flu vaccine, the ...
- BiondVax Welcomes New Chairman of the Board and Announces Second Quarter 2019 Financial Resultson August 28, 2019 at 4:45 am
Recent events have positioned BiondVax to become a successful manufacturer and marketer of its M-001 universal flu vaccine candidate. In July we closed on a financing of US$20M predominantly ...
via Bing News